1. Introduction {#sec1}
===============

Aggressive pituitary tumors are invasive macroadenomas refractory to surgical and medical treatments, showing tendency to continuous growth and implicating a bad vital prognosis \[[@B1]\]. Until some years ago, no therapies were efficacious in treating that kind of tumors. First publications of treatment with the alkylating agent temozolomide (TMZ) appeared in 2006 \[[@B2], [@B3]\] and since then, variable responses to this drug have been reported in a limited number of cases with tumor volume reduction and control of the disease in some of them. We present here our experience with the use of temozolomide in six patients with different variants of aggressive pituitary tumors.

2. Patients and Methods {#sec2}
=======================

Six patients with intention-to-treat with TMZ, presenting different types of aggressive pituitary tumors, were evaluated. They were 5 women aged 34--52 and one 78-year-old man. They all presented macroadenomas (more than 10 mm) with cavernous sinus invasion, two of them with third par palsies and one with bitemporal hemianopsia. The only male patient had pituitary carcinoma (malignant prolactinoma) with an isolated parietal metastasis which was first biopsied and then surgically excised. All patients had had unsuccessful previous pituitary surgery (from 1 to 5 times), radiotherapy in 3, and conventional drug treatment in 4 of them, aimed at controlling hyperfunction and/or tumor volume ([Table 1](#tab1){ref-type="table"}). The definition of aggressive pituitary tumor was based on clinical grounds (invasive macroadenomas refractory to surgical and medical treatments, showing tendency to continuous growth) as previously stated. We use the denomination*pituitary carcinoma* when extrapituitary presence of tumor (metastasis) is found. Temozolomide was administered as oral pills in variable doses, from 140 to 320 mg/day for 5 days every month, for at least 3 months before evaluating results. TMZ administration was preceded by the oral intake of ondansetron, as antiemetic prevention. Hematologic and liver function tests were performed before each cycle of therapy. Results of treatment were evaluated by monthly clinical examination and pituitary MRI after at least 3 months of therapy; computerized visual field examination and routine hormone tests were also made, when indicated.

For determinations of MGMT and marker of cell proliferation Ki67 on pathological specimens, all blocks were formalin buffer fixed and paraffin embedded. Cuts of 3-4 microns were made and stained with hematoxylin and eosin. Immunohistochemical determinations for adenohypophyseal hormones GH, FSH, LH, and TSH were made by using rabbit polyclonal Cell Marque (<http://www.cellmarque.com/>) antibodies whereas for PRL and ACTH, rabbit polyclonal DAKO (<http://www.dako.com/>) antibodies were employed. Ki67 and O^6^-methylguanine-DNA methyltransferase Ab-1 (MGMT) were measured by using mouse monoclonal antibodies from Thermo Scientific (<http://www.thermoscientific.com/>) in a 1 : 20 dilution. Immunostaining for MGMT was considered negative when lower than 10%.

3. Results {#sec3}
==========

[Figure 1](#fig1){ref-type="fig"} shows a MGMT-negative macrocorticotropinoma study of patient GM as compared to a MGMT-positive glioblastoma. [Table 2](#tab2){ref-type="table"} shows the results of MGMT and Ki67 immunohistochemistry, individual doses administered, length of therapy, and clinical outcome in the six patients.

Drug therapy effect could not be evaluated in patients JB and SA because they failed to complete a 3-month treatment. JB had a malignant prolactinoma with brain metastases which deceased after the first administration of TMZ and SA developed severe thrombocytopenia and neutropenia after the first cycle of therapy. In two more patients TMZ was stopped after 4 (LC) and 6 (DDO) months of treatment, because it was considered ineffective in reducing tumor size. The two last patients having macrocorticotropinoma and Cushing\'s disease have been reported in detail elsewhere \[[@B4]\]. They showed clinical response after just 3-4 cycles of administration of TMZ with remission of ocular signs, normalization of cortisol alterations, and significant shrinkage (more than 50%) of the tumors, which completely disappeared one year later and, most interestingly, long time (19--30 months) after stopping therapy the patients remained well with no signs of tumor relapse \[[@B4]\].

4. Discussion {#sec4}
=============

Frequency of pituitary tumors appears to be higher than previously suspected, as high as 1 in 1000 of the general population \[[@B5], [@B6]\]. They are usually benign and in most cases controlled by surgery, radiation, or medical treatments. In 2004 the World Health Organization defined as "*atypical*" those tumors exhibiting a MIB-1 (Ki-67) proliferative index \>3%, strong p53 immunoreactivity, and increased mitotic activity \[[@B7]\]. They make up 15% of resected pituitary tumors \[[@B8]\]. Up to 45% of macroadenomas show signs of invasion of the sphenoid or cavernous sinus \[[@B9]\]. The concept of  "*aggressive*" pituitary tumors represents a clinical appreciation to designate tumors that may recur quickly after surgery, grow into the cavernous sinus or skull base, and show resistance to the usual therapeutic means. The name pituitary*carcinoma* is reserved for those tumors with neural or extraneural metastases which make up less than 1% of the totality of pituitary tumors. It has to be emphasized that they do not show histological differences with other aggressive tumors save for the existence of metastases \[[@B10]\].

So called silent pituitary adenomas are tumors, mainly gonadotrope, corticotrope, and somatotrope, having an aggressive behavior, with frequent recurrences which made up 9% in 100 samples studied retrospectively \[[@B11]\]. They can be classified as "*silent*," with immunohistochemical evidence but*no* biochemical or clinical evidence of hormone excess, or "*clinically silent*" with immunohistochemical*and* biochemical evidence but*no* clinical evidence of hormone excess.

Temozolomide is an alkylating drug which has been used mainly in the treatment of glioblastoma multiforme but also for colorectal cancer and melanoma \[[@B12]--[@B14]\]. This drug has been used for the treatment of pituitary carcinoma and aggressive adenoma from the year 2006 onwards \[[@B2], [@B3]\]. Its mechanism of action is through sticking an alkyl group to DNA bases, principally guanine, which induces methylation. Subsequently, it provokes the fragmentation of DNA by repairing enzymes in its attempt to replace the alkylated bases \[[@B15]\]. Up to now, around 105 pituitary tumors treated with TMZ have been reported in the literature with variable results ([Table 3](#tab3){ref-type="table"}) \[[@B4], [@B16]--[@B53]\]. More than half (\~60%) were aggressive adenomas, the remaining being pituitary carcinomas. Most were functioning tumors, especially corticotropinomas and prolactinomas (\~80%). Global efficacy of TMZ therapy oscillated between 55% for aggressive adenomas and 58% for pituitary carcinomas, but it has to be underlined that criteria for efficacy were quite diverse, going from variable reduction to "stabilization" in tumoral size. It has to be remarked that in none of the reported cases a sustained disappearance of tumor after stopping TMZ was described. As far as aggressive macrocorticotropinomas are concerned, we were able to find 37 published cases silent or with overt hypercortisolism. Once again, criteria employed to evaluate response were quite diverse. In just one of those cases \[[@B20]\], the tumor disappeared under treatment but if the patient was treated with a CAPTEM schema (capecitabine plus temozolomide) we cannot know which one of the two drugs was more effective.

Doses of temozolomide usually recommended in neurology are adapted to body surface and oscillate from 150 to 200 mg/m^2^ \[[@B55]\]. Doses employed in our patients were variable, but generally lower than recommended. It has to be underlined that dose amount was mostly determined by availability following individual medical coverage. Interestingly, patients MC and GM who had total remission received fixed doses of 250 mg/d and 180 mg/d, respectively, while, if adapted to body surface area, those figures should have been 291--388 mg/d for MC and 273--364 mg/d for GM. The role that the DNA repairing systems may play in the effectiveness of temozolomide is controversial, especially concerning MGMT. This enzyme can reverse methylation of the guanine residues, thus antagonizing the effect of the drug. It has been reported that a low expression or the absence of this enzyme strongly correlates with the response to TMZ \[[@B15]\]. This has been challenged by other authors, who failed to find such a correlation \[[@B21], [@B23]\]. It has been proposed that the preservation of another enzyme system, MSH6 (DNA mismatch repair protein), correlated better with the response to TMZ than the absence of MGMT \[[@B23], [@B55]\].

In our series, the five patients in whom we were able to measure MGMT failed to show a significant expression (less than 5%); two of them having aggressive corticotropinoma had excellent clinical responses to temozolomide. Nevertheless, this does not enable us to extrapolate any conclusions at this respect, since two other MGMT-negative patients who completed the minimum period of treatment failed to show a response.

For a more rational use of TMZ several points deserve clarification: What should be the starting and maintenance doses? How can efficacy be defined? How long should the treatment be given? How big is the mutagenic risk? What is the recurrence risk after stopping TMZ? What is the probability of relapse with resistance to TMZ after stopping a successful therapy?

In conclusion, although less common, clinically aggressive pituitary tumors are not at all exceptional and pose special therapeutic challenges because surgery and radiotherapy are frequently useless and usual drug therapy is of variable and unpredictable efficacy. So called "silent" tumors appear to be particularly aggressive and, although less frequent, invasive corticotropinomas may present a difficult challenge as well, since besides local complications, they put life at risk because of the metabolic consequences of excess cortisol secretion. Temozolomide may be a salvage drug in selected cases, mainly in prolactinoma and corticotrope tumors. Cooperative work on a greater number of cases of aggressive pituitary tumors should be of the outmost importance to establish the indications, doses, and duration of temozolomide administration.

The authors are deeply indebted to Drs. Mariano Volpacchio and Santiago Rossi, from the Centro de Diagnóstico Dr. Enrique Rossi, Buenos Aires, who generously provided gratuitous control MRI in patient MC.
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![The upper panel (a) shows a diffuse positive MGMT control (glioblastoma). The lower panel (b) corresponds to a negative MGMT immunostaining of macrocorticotropinoma in patient GM.](IJE2015-587893.001){#fig1}

###### 

Main clinical traits of 6 patients with intention-to-treat with temozolomide.

  Patient   Sex   Age   Tumor type   Number of previous surgeries   RxT   Previous drug therapy
  --------- ----- ----- ------------ ------------------------------ ----- -----------------------
  JB        M     78    PRL Ca       1                              Yes   CAB
  SA        F     47    CNFPA        3                              No    CAB
  LC        F     34    GH-oma       2                              No    CAB, SSAs
  DDO       F     39    NS           2                              Yes   None
  CM        F     42    CD           1                              No    None
  GM        F     52    CD           5                              Yes   KNZ

PRLCa: prolactin carcinoma; GH-oma: somatotropinoma; CNFPA: clinically nonfunctioning pituitary adenoma; NS: Nelson\' syndrome; CD: Cushing\'s disease; RxT: radiotherapy; CAB: cabergoline; SSAs: somatostatin analogs; KNZ: ketoconazole.

###### 

Results of MGMT and Ki67 immunohistochemistry, doses, length of therapy, and clinical outcome in 6 patients with intention-to-treat with TMZ.

  Patient   Tumor type   MGMT   Ki67   TMZ mg/d   Months   Outcome
  --------- ------------ ------ ------ ---------- -------- -----------
  JB        PRL Ca       (−)    10%    140        1        Death
  SA        CNFPA        ND     2%     150        1        Failure
  LC        GH-oma       (−)    3%     320        4        Failure
  DDO       Nelson\'s    (−)    1%     240        6        Failure
  CM        CD           (−)    6%     250        13       Remission
  GM        CD           (−)    4%     180        29       Remission

###### 

Literature update on aggressive pituitary adenomas and carcinomas.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author, year \                          Sex/age                 Tumor type                        Ki67 (%)         MGMT                            TMZ (mg/m^2^) & schedule (no. cycles)             MRI (% shrinkage)                             Clinical outcome
  \[reference\]                                                                                                                                                                                                                                      
  --------------------------------------- ----------------------- --------------------------------- ---------------- ------------------------------- ------------------------------------------------- --------------------------------------------- ---------------------------
  Thearle et al., 2011 \[[@B16]\]         M/50                    ACTH SA Ad → Ca → NS              31               NA                              200 × 5/28 + CAP (4)                              Reduced (75)                                  Death

                                                                                                                                                                                                                                                     

  Dillard et al., 2011 \[[@B17]\]         M/56                    ACTH Ad                           5-6              NA                              150--200 × 5/28 (4)                               Reduced (60)                                  CR

                                                                                                                                                                                                                                                     

  Annamalai et al., 2012 \[[@B18]\]       M/65                    ACTH Ca                           5--15            Low                             200 × 5/28 (15)                                   PR of METS                                    "Remained well"

                                                                                                                                                                                                                                                     

  Moshkin et al., 2011 \[[@B19]\]         M/46                    ACTH SA Ad → Ca                   1--5             (+)                             200 × 5/28 (16)                                   No change                                     Progression

                                                                                                                                                                                                                                                     

  Zacharia et al., 2014 \[[@B20]\]        M/50                    ACTH Ad                           \<5              (−)                             150, 5/28 + CAP (30)                              SD                                            PR

  F/46                                    ACTH Ad                 15--20                            (−)              150, 5/28 + CAP (32)            CR                                                CR                                            

  M/44                                    ACTH Ad                 \<5                               (−)              150, 5/28 (45) + CAP + A-SST    CR                                                CR                                            

                                                                                                                                                                                                                                                     

  Raverot et al., 2010 \[[@B21]\]         M/31                    ACTH Ca → NS                      20               50 (+)                          150--200 × 5/28                                   No change                                     NA

  M/49                                    ACTH Ad                 20                                \<1              150--200 × 5/28                 No change                                         NA                                            

  M/38                                    ACTH Ca                 10                                30 (+)           150--200 × 5/28                 SR                                                "Significant response"                        

  F/42                                    ACTH Ad                 0.5                               0                150--200 × 5/28                 SR                                                "Significant response"                        

  M/32                                    PRL Ca                  NA                                NA               150--200 × 5/28 (24)            Reduced (60), disappearance of METS               NA                                            

  M/52                                    PRL Ad                  0.5                               30               150--200 × 5/28 (8)             No change                                         NA                                            

  M/54                                    PRL Ca                  1                                 0                150--200 × 5/28 (5)             No change                                         NA                                            

  F/30                                    PRL Ca                  10                                100              150--200 × 5/28 (3)             No change                                         NA                                            

                                                                                                                                                                                                                                                     

  Bush et al., 2010 \[[@B22]\]            NA                      Null cell Ad                      \<3              ---                             75 × 21/7 (10)                                    Reduced (20)                                  Stable

  NA                                      ACTH Ad                 18                                \<10             75 × 21/28 (11)                 Reduced (80)                                      "Improved"                                    

  NA                                      NF Ad                   \<3                               10--50           75 × 21/(13)                    SD                                                SD                                            

  NA                                      Null cell Ad            6                                 \>50             75 × 21/7 (10)                  SD                                                SD                                            

  NA                                      PRL Ad                  NA                                \<10             75 × 21/7 (11)                  Reduced (80)                                      "Improved"                                    

  NA                                      Null cell Ca            \>20                              \>50             75 × 21/7 (2)                   SD × 2 months                                     NA                                            

  NA                                      Null cell Ca            \>20                              \<10             75 × 21/7 (7)                   Progression                                       Death                                         

                                                                                                                                                                                                                                                     

  Hirohata et al., 2013 \[[@B23]\]        M/59                    NF Ca                             74.6             (+)                             150--200 × 5/28 (5)                               PR                                            NA

  F/42                                    ACTH Ca                 3.4                               (−)              150--200 × 5/28 (7)             PR                                                NA                                            

  F/60                                    PRL Ca                  18.7                              (−)              150--200 × 5/28 (13)            CR                                                NA                                            

  M/23                                    NF Ca                   2.5                               (+)              150--200 × 5/28 (7)             SD                                                NA                                            

  F/53                                    ACTH Ca (Crooke cell)   2.0                               (+)              150--200 × 5/28 (20)            CR                                                NA                                            

  F/60                                    PRL Ca                  27.8                              (+)              150--200 × 5/28 (12)            PR                                                NA                                            

  M/57                                    ACTH Ca                 10                                (+)              150--200 × 5/28 (8)             SD                                                NA                                            

  F/73                                    NF Ca                   5.6                               (−)              150--200 × 5/28 (22)            PR                                                NA                                            

  M/60                                    PRL Ca                  40.2                              (−)              150--200 × 5/28 (24)            PR                                                NA                                            

  F/61                                    NF Ca                   12.2                              (+)              75 × 6 weeks + RT               Progression                                       NA                                            

  F/66                                    PRL Ad                  9.4                               (−)              75 × 6 weeks + RT               CR                                                NA                                            

  F/49                                    PRL Ad                  3.9                               (−)              NA (3)                          Progression                                       NA                                            

  F/45                                    ACTH Ad (Crooke cell)   46.8                              (+)              150--200 × 5/28 (11)            PR                                                NA                                            

                                                                                                                                                                                                                                                     

  Losa et al., 2010 \[[@B24]\]            M/64                    ACTH Ad                           NA               NA                              150--200 × 5/28                                   Progression                                   Death

  M/52                                    ACTH Cd                 1                                 (−)              150--200 × 5/28                 "Response"                                        Required GC therapy                           

  F/55                                    ACTH Ad → NS            5                                 (−)              150--200 × 5/28                 SD                                                NA                                            

  F/53                                    ACTH Ad                 2.5                               (+)              150--200 × 5/28                 Progression                                       No change                                     

  M/62                                    PRL Ad                  9                                 (−)              150--200 × 5/28                 SD                                                NA                                            

  F/57                                    PRL Ad                  NA                                Noninformative   150--200 × 5/28                 "Response"                                        "Improved"                                    

                                                                                                                                                                                                                                                     

  Moyes et al., 2009 \[[@B25]\]           F/64                    ACTH Ad → NS                      "High"           (−)                             200 × 5/28 (6)                                    "Marked shrinkage"                            "Improved"

                                                                                                                                                                                                                                                     

  Takeshita et al., 2009 \[[@B26]\]       F/46                    ACTH Ca → NS                      \~3              \<5 (−)                         150--200 × 5/28 (23)                              CR tumor + METS                               Required GC therapy

                                                                                                                                                                                                                                                     

  Curtò et al., 2010 \[[@B27]\]           M/42                    ACTH Ca                           2--18            \<5 (−)                         150--200 × 5/28 (17)                              Reduced (\>90)                                "Improved"

                                                                                                                                                                                                                                                     

  Mohammed et al., 2009 \[[@B28]\]        F/43                    ACTH Ad                           NA               (−)                             150--200 × 5/28 (12)                              PR                                            "Improved"

  M/60                                    ACTH Ca → NS            NA                                (+)              150--200 × 5/28 (12)            PR                                                "Improved"                                    

                                                                                                                                                                                                                                                     

  Bode et al., 2010 \[[@B29]\]            NA                      ACTH Ca → NS                      NA               NA                              150 × 5/28                                        PR                                            NA

                                                                                                                                                                                                                                                     

  Jouanneau et al., 2012 \[[@B30]\]       NA                      SA → Ca                           NA               NA                              200 × 5/28                                        NR                                            NA

                                                                                                                                                                                                                                                     

  Asimakopoulou et al., 2014 \[[@B31]\]   F/55                    ACTH Ad (Crooke cell)             1                NA                              150--200 × 5/28                                   CR                                            CR

                                                                                                                                                                                                                                                     

  Bengtsson et al., 2015 \[[@B32]\]       F/71                    ACTH Ad                           50               90                              150--200 × 5/28                                   SD                                            NA

  F/31                                    GH Ad                   7                                 9--100           150--200 × 5/28 (6)             Reduced (50)                                      Regrowth after TMZ stop                       

  F/13                                    GH Ad                   5                                 95               150--200 × 5/28                 NA                                                NA                                            

  M/33                                    PRL-GH Ad               23                                10               150--200 × 5/28 (3)             Reduced (35)                                      SD 25 months after TMZ                        

  M/22                                    PRL Ad                  8                                 90               150--200 × 5/28 (15)            Reduced (25)                                      Death                                         

  M/34                                    PRL Ad                  6                                 9--100           150--200 × 5/28 (4)             Stable 40 m after TMZ                             PR                                            

  M/45                                    PRL Ad                  2                                 100              150--200 × 5/28 (5)             Progression                                       PR                                            

  M/55                                    PRL Ad                  10                                20               150--200 × 5/28 (11)            Reduced (66)                                      Death                                         

  M/60                                    PRL Ad                  2                                 9                150--200 + CAB (21)             Reduced (80)                                      Death                                         

  M/68                                    PRL Ad                  NA                                                 150--200 × 5/28                 Progression                                       Death                                         

  M/23                                    PRL Ad                  41                                100              150--200 × 5/28 (4)             Progression                                       Death                                         

  M/22                                    NF Ad                   2                                 9                150--200 × 5/28 (12)            Reduced (55)                                      SD 69 m after TMZ                             

  M/45                                    NF Ad                   2                                 100              150--200 × 5/28 (18)            Reduced (28)                                      NA                                            

  F/52                                    NF Ad                   10                                90               150--200 × 5/28 (5)             Progression                                       Death                                         

  M/59                                    NF Ad                   10                                90               150--200 × 5/28 (6)             Progression                                       Death                                         

  M/57                                    NF Ad                   3.3                               95               150--200 × 5/28                 Progression                                       Death                                         

  M/51                                    ACTH Ca                 80                                0--60            150--200 × 5/28                 NA                                                Death                                         

  M/62                                    ACTH Ca (NS)            10                                95               150--200 × 5/28                 NA                                                Lost to follow-up                             

  M/70                                    ACTH Ca                 70                                9                150--200 × 5/28                 NA                                                NA                                            

  M/46                                    GH Ca                   60                                90               150--200 × 5/28                 NA                                                Death                                         

  F/40                                    GH Ca                   20                                9                150--200 × 5/28                 CR                                                CR after 48 months                            

  F/49                                    PRL-GH Ca               5                                 9                150--200 × 5/28                 CR                                                CR after 91 months                            

  F/32                                    PRL Ca                  20                                50               150--200 × 5/28                 NA                                                Death                                         

  F/59                                    PRL Ca                  10                                NA               150--200 × 5/28                 NA                                                PR                                            

                                                                                                                                                                                                                                                     

  Vieira Neto et al., 2013 \[[@B33]\]     F/54                    GH S Ca                           2.6              68                              150--200 × 5/28                                   SD                                            NA

                                                                                                                                                                                                                                                     

  Morokuma et al., 2012 \[[@B34]\]        M/58                    NF Ca/NEM-1                       7.6              (−)                             75/d × 42 days; then 192 × 5/28 + RT (20)         "Visibly declined"                            "Improved"

                                                                                                                                                                                                                                                     

  Zhong et al., 2014 \[[@B35]\]           F/30                    NF Ad                             20               NA                              200/d × 5/4 consecutive weeks/2 months + RT (4)   CR                                            NA

                                                                                                                                                                                                                                                     

  Syro et al., 2009 \[[@B36]\]            M/70                    Gn Ad                             2--6             30--\>50                        200 × 5/28 (6)                                    "Minor reduction" and intratumoral necrosis   Death

                                                                                                                                                                                                                                                     

  Hagen et al., 2009 \[[@B37]\]           F/48                    PRL Ad to mixed PRL-GH Ad to Ca   5                (−)                             150--200 + CAB/STT-A                              Reduced (62)                                  "Improved"

  M/60                                    PRL Ad                  \~2                               (−)              150--200 + CAB                  Reduced (80)                                      "Improved"                                    

  M/20                                    NF Ad                   \~2                               Few (+)          150--200                        Reduced (55)                                      "Improved"                                    

                                                                                                                                                                                                                                                     

  Mendola et al., 2014 \[[@B38]\]         M/58                    NS Ca                             10               NA                              160 × 5/28 (1)                                    No                                            No change

                                                                                                                                                                                                                                                     

  Strowd et al., 2015 \[[@B39]\]          F/44                    PRL Ad                            NA               NA                              150--200 × 5/28 (3 months)                        "Reduction in tumor size"                     PR

                                                                                                                                                                                                                                                     

  Ceccato et al., 2015 \[[@B40]\]         F/67                    NF Ad                             \<3              NA                              150--200 × 5/28                                   Progression                                   No change

  F/39                                    GH Ad                   \<3                               NA               150--200 × 5/28                 Progression                                       No change                                     

  M/40                                    NF Ad                   \<3                               NA               150--200 × 5/28                 Decreased (49)                                    NA                                            

  M/32                                    ACTH Ad                 \<3                               NA               150--200 × 5/28                 Decreased (63)                                    No change                                     

  M/47                                    NF Ad → ACTH            \<3                               NA               150--200 × 5/28 + pasireotide   Decreased (21)                                    No change                                     

                                                                                                                                                                                                                                                     

  Philippon et al., 2012 \[[@B41]\]       M/41                    PRL Ca/MEN-1                      NA               NA                              200 × 5/28 (24)                                   Decreased (62)                                "Improved"

                                                                                                                                                                                                                                                     

  Fadul et al., 2006 \[[@B42]\]           M/38                    NF Ca                             1                NA                              200 × 5/23 (12)                                   PR                                            PR

  M/26                                    PRL Ca                  10                                                 200 × 5/23 (10)                 PR                                                PR                                            

                                                                                                                                                                                                                                                     

  Kovacs et al., 2007 \[[@B43]\]          M/46                    PRL Ca                            40--60           NA                              200 × 5/28 (7)                                    "Shrinkage"                                   "Improved"

                                                                                                                                                                                                                                                     

  Cornell et al., 2013 \[[@B44]\]         M/40                    ACTH Ad                           5--7             NA                              200 × 5/28 (3)                                    Progression                                   No change

                                                                                                                                                                                                                                                     

  Phillips et al., 2012 \[[@B45]\]        M/25                    PRL Ad                            23               NA                              350 × 5 (1)                                       No change                                     Death

                                                                                                                                                                                                                                                     

  Rotondo et al., 2012 \[[@B46]\]         F/49                    Crooke cell Ad                    5--8             (−)                             85 p.o daily + SRT                                NA                                            NA

                                                                                                                                                                                                                                                     

  Arnold et al., 2012 \[[@B47]\]          F/61                    ACTH Ca                           NA               NA                              NA (12)                                           "Resolved"                                    PR

                                                                                                                                                                                                                                                     

  Morin et al., 2012 \[[@B48]\]           M/22                    GH Ad                             3-4              NA                              200 × 5/28 (5)                                    No change                                     Increased signs

                                                                                                                                                                                                                                                     

  Whitelaw et al., 2012 \[[@B49]\]        M/34                    PRL Ad                            15               (−)                             200 × 5/28 (6)                                    "Dramatic reduction"                          "Significant improvement"

  M/32                                    PRL Ad                  8                                 (−)              200 × 5/28 (6)                  "Substantial reduction"                           "Significant improvement"                     

  M/13                                    PRL Ad                  4                                 (−)              200 × 5/28 (12)                 PR                                                PR                                            

                                                                                                                                                                                                                                                     

  Ersen et al., 2012 \[[@B50]\]           NA                      Gn Ad                             NA               Two zones: (−) and (+), 60%     200 × 5/28 (14)                                   SD                                            "Clinical improvement"

                                                                                                                                                                                                                                                     

  Scheithauer et al., 2012 \[[@B51]\]     F/13 months             Pituitary blastoma                NA               Varied from 40 to 60%           100 × 5/28 (12 + 6)                               Progression                                   NA

                                                                                                                                                                                                                                                     

  Ortiz et al., 2012 \[[@B52]\]           M/38                    ACTH Ad → Ca                      NA               High                            200 × 5/28 (8)                                    No change                                     Progression

                                                                                                                                                                                                                                                     

  Batisse et al., 2013 \[[@B53]\]         M/47                    GH Ad                             (−)              High                            200 × 5/28 (3)                                    Progression                                   No significant response

                                                                                                                                                                                                                                                     

  Bruno et al., 2015 \[[@B4]\]            F/52                    ACTH Ad                           6                (−)                             150--200 × 5/28 (29)                              CR                                            CR

  F/42                                    ACTH Ad                 4                                 (−)              150--200 × 5/28 (12)            CR                                                CR                                            
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Ad: adenoma; Ca: carcinoma; SA: silent adenoma; NS: Nelson\'s syndrome; NF: nonfunctioning; PRL: lactotrope; ACTH: corticotrope; GH: somatotrope; Gn: gonadotrope; MRI: magnetic resonance imaging; NA: not available; RT: radiotherapy; CR: complete response; PR: partial response; SR: "significant" reduction; METS: metastases; SD: stable disease; CAB: cabergoline; STT-A: somatostatin agonist; CAP: capecitabine; →: change; (og): ongoing.
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